Biocryst Pharma Inc (BCRX) 4.23 $BCRX BioCryst
Post# of 273258
Posted On: 09/02/2016 1:15:59 PM
Biocryst Pharma Inc (BCRX) 4.23 $BCRX
BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8
GlobeNewswire - Wed Aug 31, 1:40PM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at Baird's 2016 Global Healthcare Conference in New York on Thursday, September 8th at 12:50 p.m. Eastern Time.
BCRX: 4.23 (+0.07)
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.23 (+0.07), ALNY: 69.49 (+0.47), HEB: 1.39 (+0.01), VBLT: 4.06 (unch)
After Yesterday's Decline of 5.13%, BioCryst Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Aug 25, 3:17PM CDT
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $4.14 to a high of $4.40. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $4.22 on volume of 722,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCRX: 4.23 (+0.07)
BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema
GlobeNewswire - Thu Aug 11, 9:18AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (HAE).
BCRX: 4.23 (+0.07)
Biotech's in the News
ACCESSWIRE - Wed Aug 10, 9:19AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 10, 2016 / The name of the game in evaluating development stage biotechnology is patents. How many do they have, how useful are they, and how likely is it they will produce treatments or products for the market? Depending on the combination of answers said company could become an enticing acquisition candidate for some of the bigger fish in the biotech world. Which tends to pay companies and their investors premiums to circumvent their lack of R&D.
BCRX: 4.23 (+0.07), BLCM: 17.33 (-0.14)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 18.1%
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:15AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose over 18% in the last trading session.
BCRX: 4.23 (+0.07), EARS: 1.75 (+0.04)
Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Fri Aug 05, 3:03AM CDT
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $4.00 on volume of 1.9 million shares, above average daily volume of 1.1 million. There is potential upside of 306.3% for shares of BioCryst Pharmaceuticals based on a current price of $4.00 and an average consensus analyst price target of $16.25. The stock should hit resistance at its 200-day moving average (MA) of $8.10, as well as support at its 50-day MA of $2.84.
BCRX: 4.23 (+0.07)
BioCryst Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 5:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2016.
BCRX: 4.23 (+0.07)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 4.23 (+0.07)
BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 4.23 (+0.07)
BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 4.23 (+0.07)
BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 4.23 (+0.07)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 4.23 (+0.07), VRTX: 94.78 (+0.03), GILD: 76.95 (-0.47), SRPT: 27.20 (+0.64), ALXN: 123.87 (-1.76), CTIC: 0.39 (unch), REGN: 388.20 (-5.20)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 4.23 (+0.07), PETX: 8.84 (-0.08)
Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 82.63 (+1.01), BCRX: 4.23 (+0.07), DO: 16.48 (-0.03), CNA: 33.48 (+0.22)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 4.23 (+0.07)
BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8
GlobeNewswire - Wed Aug 31, 1:40PM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at Baird's 2016 Global Healthcare Conference in New York on Thursday, September 8th at 12:50 p.m. Eastern Time.
BCRX: 4.23 (+0.07)
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.23 (+0.07), ALNY: 69.49 (+0.47), HEB: 1.39 (+0.01), VBLT: 4.06 (unch)
After Yesterday's Decline of 5.13%, BioCryst Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Aug 25, 3:17PM CDT
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $4.14 to a high of $4.40. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $4.22 on volume of 722,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCRX: 4.23 (+0.07)
BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema
GlobeNewswire - Thu Aug 11, 9:18AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in the APeX-1 clinical trial of BCX7353 for the oral treatment of hereditary angioedema (HAE).
BCRX: 4.23 (+0.07)
Biotech's in the News
ACCESSWIRE - Wed Aug 10, 9:19AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 10, 2016 / The name of the game in evaluating development stage biotechnology is patents. How many do they have, how useful are they, and how likely is it they will produce treatments or products for the market? Depending on the combination of answers said company could become an enticing acquisition candidate for some of the bigger fish in the biotech world. Which tends to pay companies and their investors premiums to circumvent their lack of R&D.
BCRX: 4.23 (+0.07), BLCM: 17.33 (-0.14)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 18.1%
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:15AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) shares rose over 18% in the last trading session.
BCRX: 4.23 (+0.07), EARS: 1.75 (+0.04)
Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
Comtex SmarTrend(R) - Fri Aug 05, 3:03AM CDT
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $4.00 on volume of 1.9 million shares, above average daily volume of 1.1 million. There is potential upside of 306.3% for shares of BioCryst Pharmaceuticals based on a current price of $4.00 and an average consensus analyst price target of $16.25. The stock should hit resistance at its 200-day moving average (MA) of $8.10, as well as support at its 50-day MA of $2.84.
BCRX: 4.23 (+0.07)
BioCryst Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 5:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2016.
BCRX: 4.23 (+0.07)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 4.23 (+0.07)
BioCryst to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu May 26, 7:55AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
BCRX: 4.23 (+0.07)
BioCryst Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 5:44AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2016.
BCRX: 4.23 (+0.07)
BioCryst to Announce First Quarter 2016 Financial Results May 5
GlobeNewswire - Thu Apr 21, 5:48AM CDT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.
BCRX: 4.23 (+0.07)
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Arpita Dutt - Zacks Investment Research - Wed Feb 10, 10:02AM CST
Disappointing pipeline and regulatory updates from companies like CTI BioPharma (CTIC) and Sarepta (SRPT) and earnings misses from Alexion and Regeneron were the highlights this week.
BCRX: 4.23 (+0.07), VRTX: 94.78 (+0.03), GILD: 76.95 (-0.47), SRPT: 27.20 (+0.64), ALXN: 123.87 (-1.76), CTIC: 0.39 (unch), REGN: 388.20 (-5.20)
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Jumps 6.2%
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:35AM CST
BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BCRX: 4.23 (+0.07), PETX: 8.84 (-0.08)
Company News for February 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 9:10AM CST
Companies in the News are; HAS,DO,CNA,BCRX
HAS: 82.63 (+1.01), BCRX: 4.23 (+0.07), DO: 16.48 (-0.03), CNA: 33.48 (+0.22)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of BioCryst Pharmaceuticals, Inc. -- BCRX
BusinessWire - Mon Feb 08, 11:04AM CST
Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
BCRX: 4.23 (+0.07)
(0)
(0)Scroll down for more posts ▼